A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFN in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

• Status: RECRUITING
• Trial end date: 2027-07-01

Summary

This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFN compared to PEG-IFN in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

• Phase: PHASE2

Details

• Lead Sponsor: Brii Biosciences Limited